[^1]
| Beta-Synuclein (SNCB) |
|---|
| Protein Name | Beta-Synuclein |
| Gene | [SNCB](/genes/sncb) |
| UniProt ID | [Q9NB0](https://www.uniprot.org/uniprot/Q9NB0) |
| PDB ID | 1xnx, 2m2a |
| Molecular Weight | 14 kDa |
| Subcellular Localization | Cytoplasm, Presynaptic terminals |
| Protein Family | Synuclein family |
Beta-Synuclein (SNCB) is a 134-amino acid protein belonging to the synuclein family, which also includes alpha-synuclein and gamma-synuclein. While alpha-synuclein is infamous for its role in Parkinson's disease, beta-synuclein has emerged as an important modulator of synucleinopathies with complex neuroprotective and pathogenic roles.
¶ Gene and Protein Structure
The SNCB gene is located on chromosome 5q35.2 and encodes a protein of 134 amino acids. It is expressed predominantly in the brain, with highest levels in the hippocampus, cortex, and olfactory bulb.
¶ Protein Domains
Beta-synuclein has characteristic synuclein features:
- N-terminal domain (1-60): Contains the characteristic KTKEGV repeat motif
- Central region (61-95): Non-Aβ component (NAC) - but lacks full hydrophobic region
- C-terminal domain (96-134): Acidic tail with proline-rich region
- Key difference: Lacks the central hydrophobic NAC region found in alpha-synuclein
Beta-synuclein has several physiological roles:
- Chaperone activity: Modulates SNARE complex assembly
- Synaptic plasticity: Regulates neurotransmitter release
- Vesicle trafficking: Associates with synaptic vesicles
- Aggregation inhibition: May counteract alpha-synuclein aggregation
- Chaperone function: Protects against cellular stress
- Protein homeostasis: Supports cellular protein quality control
SNCB has complex relationships with PD:
- Aggregation modulation: Beta-synuclein may reduce alpha-synuclein aggregation
- Genetic variants: SNCB mutations are rare but can cause parkinsonism
- Lewy bodies: Generally not a major component of Lewy bodies
- Dementia with Lewy Bodies: May be involved in disease progression
- Lewy body composition: Present in some DLB Lewy bodies
- Aggregation: May co-aggregate with alpha-synuclein
- Cognitive symptoms: Linked to cortical involvement
In AD, beta-synuclein shows:
- Amyloid interaction: May bind to Aβ plaques
- Synaptic dysfunction: Altered expression patterns
- Cognitive correlation: Associated with cognitive decline
Beta-synuclein is a therapeutic target:
- Aggregation modulators: Enhancing beta-synuclein's protective effects
- Chaperone therapeutics: Small molecule chaperones
- Gene therapy: Increasing beta-synuclein expression
- CSF levels: May serve as a biomarker
- Genetic testing: SNCB variants for risk assessment